Forty Seven, Inc. (Nasdaq: FTSV), a clinical stage immuno-oncology company, today announced that it has commenced an underwritten public offering of $75,000,000 of shares of its common stock. All of the shares of common stock are being offered by Forty Seven. In connection with this offering, Forty Seven expects to grant the underwriters a 30-day option to purchase up to $11,250,000 of additional shares of common stock.

Morgan Stanley & Co. LLC and Credit Suisse Securities (USA) LLC are acting as joint book-running managers for the offering. The offering is subject to market conditions, as well as Nasdaq approval, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.